Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Cara Therapeutics (NASDAQ: CARA) after oral CR845 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE